Inventor

John G. Babish

Inventor

Brooktondale, NY, US

Overview

1983–2021

Patent span

Human necessities

Primary field (CPC A)

Patents· 52 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary

A61KPreparations for medical, dental or toiletry purposes45%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations28%

A23LFoods, foodstuffs or non-alcoholic beverages, not otherwise provided for7%

G01NInvestigating or analysing materials by determining their chemical or physical properties6%

A23VIndexing scheme relating to foods, foodstuffs or non-alcoholic beverages and lactic or propionic acid bacteria used in foodstuffs or food preparation4%

Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests4%

A01NPreservation of bodies of humans or animals or plants or parts thereof2%

A23CDairy products, e.g. milk, butter or cheese1%

A23KFodder1%

A23Y1%

PatentTitleYear

11,122,832Methods and compositions to improve weight loss and cardiometabolic health beyond diet and excercise2021 10,434,131Phytocomplexes exhibiting multiple, synergistic antioxidant activities useful in foods, dietary supplements, cosmetics and pharmaceutical preparations2019 10,179,155Phosphodiesterase-4 inhibiting phytochemical compositions2019 9,180,155'Compositions from Nigella sativa'2015 8,557,306'Compositions that treat or inhibit pathological conditions associated with inflammatory response'2013 8,535,740'Compositions from Nigella sativa '2013 8,486,457'Compositions that treat or inhibit pathological conditions associated with inflammatory response'2013 8,263,139'Protein kinase modulation by hops and Acacia products'2012 8,257,754'Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response'2012 8,206,753'Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes'2012 8,193,201'Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines'2012 8,168,234'Compositions that treat or inhibit pathological conditions associated with inflammatory response'2012 8,142,819'Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response'2012 8,093,292'Methods for the treatment of HIV-1 related fat maldistribution, fasting hyperlipidemia and modification of adipocyte physiology'2012 8,092,846'Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines'2012 8,029,831'Formulations containing thymoquinone for urinary health'2011 8,017,651'Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia'2011 7,919,125'Modulation of inflammation by hops fractions and derivatives'2011 7,914,831'Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines'2011 7,901,713'Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops'2011 7,820,206'Modulation of inflammation by hops fractions and derivatives'2010 7,815,944'Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment of prevention of gastric toxicity'2010 7,811,610'Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity'2010 7,807,203'Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity'2010 7,794,757'Modulation of inflammation by hops fractions and derivatives'2010 7,790,205'Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response'2010 7,736,677'Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment'2010 7,722,903'Modulation of inflammation by hops fractions and derivatives'2010 7,682,636'Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2'2010 7,666,449'Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity'2010 7,431,948'Compositions that treat or inhibit pathological conditions associated with inflammatory response'2008 7,332,185'Complex mixtures exhibiting selective inhibition of cyclooxygenase-2'2008 7,279,185'Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2'2007 7,270,835'Compositions that treat or inhibit pathological conditions associated with inflammatory response'2007 7,205,151'Complex mixtures exhibiting selective inhibition of cyclooxygenase-2'2007 7,195,785'Complex mixtures exhibiting selective inhibition of cyclooxygenase-2'2007 6,979,470'Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2'2005 6,908,630'Combinations of sesquiterpene lactones and ditepene triepoxide lactones for synergistic inhibition of cyclooxygenase-2'2005 6,780,596'Methods for determining the activity of complex mixtures'2004 6,733,793'Oral composition with insulin-like activities and methods of use'2004 6,629,835'Combinations of diterpene triepoxide lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2'2003 6,506,420'Combinations of psyllium and chitosan for synergistic adsorption of triglyceride'2003 6,140,063'In vitro screening assay for identification of compounds that inhibit cytopathicity of viral infection'2000 5,833,994'Use of the AH receptor and AH receptor ligands to treat or prevent cytopathicity of viral infection'1998 5,612,188'Automated, multicompartmental cell culture system'1997 5,529,899'Immunoassay for AH receptor transformed by dioxin-like compounds'1996 5,496,703'Indirect immunoassay for dioxinlike compounds'1996 5,057,510'Use of selected pyridine-2-thione-N-oxide compounds as growth promoters for poultry'1991 4,610,993'Use of selected pyridine-N-oxide disulfide compounds to treat or prevent bovine mastitis'1986 4,609,665'Use of selected pyridine-N-oxide disulfide compounds to treat or prevent swine exudative epidermitis'1986 4,401,666'Use of metallic salts of pyridine-2-thione-N-oxide to treat or prevent bovine mastitis'1983 4,399,130'Use of metallic salts of pyridine-2-thione-N-oxide to treat or prevent swine exudative epidermitis'1983

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1983–2015Based in Ithaca, NY, US· patent location history

1996–2021Based in Brooktondale, NY, US· patent location history

2003–2013Patents assigned to METAPROTEOMICS LLC (32)· patent assignee history

2012–2013Patents assigned to BABISH JOHN G (10)· patent assignee history

2012–2013Patents assigned to BLAND JEFFREY S (9)· patent assignee history

2012–2013Patents assigned to TRIPP MATTHEW L (9)· patent assignee history

2012–2013Patents assigned to LERMAN ROBERT (5)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
METAPROTEOMICS LLC	32	2003–2013
BABISH JOHN Gself	10	2012–2013
BLAND JEFFREY S	9	2012–2013
TRIPP MATTHEW L	9	2012–2013
LERMAN ROBERT	5	2012–2013

Locations

Location	Patents	Span
Brooktondale, New York, US	43	1996–2021
Ithaca, New York, US	9	1983–2015